Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders

Area of Science:

• Cardiovascular Medicine
• Metabolic Disorders
• Molecular Biology

Background:

• Insulin resistance, hypertension, and hypercholesterolemia contribute to endothelial dysfunction and metabolic syndrome.
• Metabolic syndrome is a precursor to cardiovascular disease, driven by complex metabolic pathways.
• Insulin resistance and endothelial dysfunction are intricately linked, influencing each other's progression.

Purpose of the Study:

• To summarize common molecular therapeutic targets for insulin resistance, endothelial dysfunction, and vascular inflammation.
• To analyze the pleiotropic effects of existing cardiovascular disease, metabolic syndrome, and diabetes medications.
• To explore combined treatment strategies for metabolic disturbances and cardiovascular disease prevention.

Main Methods:

• Literature review of molecular targets and therapeutic pathways.
• Analysis of pharmacological and non-pharmacological interventions.
• Examination of drug repurposing for pleiotropic effects.

Main Results:

• Identified shared molecular targets between insulin resistance, endothelial dysfunction, and vascular inflammation.
• Highlighted the potential of pleiotropic drugs in simultaneously addressing multiple risk factors.
• Emphasized the role of combined therapies in mitigating cardiovascular disease progression.

Conclusions:

• Interconnected pathologies of insulin resistance and endothelial dysfunction necessitate integrated therapeutic approaches.
• Pleiotropic drug effects offer a unified strategy for managing metabolic syndrome and cardiovascular risk.
• Combined non-pharmacological and pharmacological interventions are crucial for preventing cardiovascular disease development.